Altos Labs launches with $3B financing and Hal Barron as CEO

19 January 2022

New biotech company Altos Labs has launched today with the aim of unraveling the deep biology of cellular rejuvenation programming, with $3 billion fully committed from renowned company builders and investors, reportedly including billionaires such as Amazon founder Jeff Bezos and Yuri Milner, a Russian-Israeli physicist who became a billionaire with his stake in Facebook and Twitter.

Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos will be initially based in the US in the San Francisco Bay Area and San Diego, and in the UK in Cambridge.

The Altos executive team will be composed of Dr Hal Barron (incoming chief executive), Dr Rick Klausner (chief scientist and founder), Hans Bishop (president and founder), and Ann Lee-Karlon (chief operating officer).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK